PO.CH01.05 · 化学

B细胞淋巴瘤中的抗增殖筛选:加纳药用植物及其植物化学关联

Antiproliferative screening in B cell lymphoma: Ghanaian medicinal plants and their phytochemical correlates

海报缩略图:B细胞淋巴瘤中的抗增殖筛选:加纳药用植物及其植物化学关联
编号 3663 展板 22 时间 4/20 02:00–05:00 区域 Section 38 主讲 Filippo Spriano, PhD
分会场 Natural Products
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Filippo Spriano1, Alberto J. Arribas1, Alberto Furlan2, Johnson Nketiah3, Barbara Z. Anibea3, Andrea Cavalli2, Afua A. Mensah1, Dorcas Osei-Safo3, Francesco Bertoni1

1Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland,2Institute of Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland,3Department of Chemistry, University of Ghana, Accra, Ghana

摘要 Abstract

中文摘要
背景。淋巴瘤仍是发病和死亡的主要原因,患者因治疗耐药和累积毒性而复发。超过60%的抗癌药物来源于植物来源的天然产物(NPs)或其衍生物。NPs增添了富含3D结构的骨架,拓宽了化学空间并可作用于"难成药"靶点。围绕NP核心的半合成可增强效力、选择性和药代动力学,同时保留与现有药物正交的新型机制,有助于绕过或延缓耐药。在此,我们研究了来源于10种加纳单一植物物种和2种确定混合物的NPs在边缘区淋巴瘤(MZL)模型(包括对BTK、BCL2和PI3K抑制存在继发性耐药的衍生株)中的抗肿瘤活性。 方法。我们在VL51、SSK41、Karpas1718亲本株及其耐药衍生株(VL51 ibrutinib耐药株、SSK41 venetoclax耐药株和Karpas1718 idelalisib耐药株)中,以10和1 μg/mL的浓度筛选了48份样品(单一物种、混合物、纯化化合物、组分、提取物),处理72小时(MTT)。活性定义为增殖抑制≥30%。选定的化学型通过LC/MS引导的分离和NMR进行鉴定。 结果。样品的活性具有异质性,全部检测读数中有7%在1 μg/mL时具活性,30%在10 μg/mL时具活性。最一致且最强效的抑制见于Dichapetalum heudelotii根部组分(DOS-19/20/21/22)和Xylopia aethiopica果实组分(DOS-34/45/47)。DOS-20含有二苯乙烯类化合物,包括(E)-康普瑞汀A-1、康普瑞汀B-1和heudelotols,在10 μg/mL时产生强而广泛的增殖抑制。富含对映-贝壳杉烷型二萜的DOS-34和-47在10 μg/mL时发挥强效增殖抑制,而在1 μg/mL时活性明显丧失,表明呈陡峭的剂量-反应行为。单一化合物己基-9-氧代癸酸酯(DOS-8)在SSK41 venetoclax耐药细胞中于10和1 μg/mL时的活性均高于亲本细胞。类似地,来源于Clausena anisata的单一化合物isomeranzin以及Xylopia + Bambusa沉淀物在SSK41 venetoclax耐药细胞中显示出更高活性。来自Aloe vera与T. officinale混合物柱层析的亚组分在SSK41细胞和Karpas1718中表现出优先活性,在Karpas1718 idelalisib耐药细胞中的活性高于亲本细胞。 讨论。我们观察到明显的化学型-活性模式:二苯乙烯类和对映-贝壳杉烷型二萜是最强效的特征谱,而生物碱类表现出更狭窄、依赖于具体情境的效应;富含脂肪酸酯的样品大多无活性。Dichapetalum和Xylopia组分陡峭的剂量依赖性及其在耐药和TP53缺陷模型中的活性,提示它们是优先的先导物,可用于作用机制研究以及针对耐药B细胞淋巴瘤的优化。
查看英文原文 English abstract
Background. Lymphomas remain a major cause of morbidity and mortality, with patients relapsing due to resistance to treatment and cumulative toxicity. Over 60% of anticancer drugs are derived from plant-derived natural products (NPs) or their derivatives. NPs add 3D-rich scaffolds that broaden chemical space and engage “hard” targets. Semi-synthesis around NP cores can enhance potency, selectivity, and pharmacokinetics, preserving novel mechanisms orthogonal to current agents, which help bypass or delay resistance. Here, we have studied NPs derived from 10 Ghanaian individual plant species and 2 defined mixtures for their anti-tumor activity in marginal zone lymphoma (MZL) models, including derivatives with secondary resistance to BTK, BCL2, and PI3K inhibition. Methods. We screened 48 samples (single species, mixtures, purified compounds, fractions, extracts) in VL51, SSK41, Karpas1718parental and their resistant derivatives (VL51 ibrutinib resistant, SSK41 venetoclax resistant, and Karpas1718 idelalisib resistant) at 10 and 1 µg/mL for 72 h (MTT). Activity was defined as ≥30% inhibition of proliferation. Selected chemotypes were assigned by LC/MS-guided isolation and NMR. Results. The samples' activity was heterogeneous, with 7% of all readouts active at 1 µg/mL and 30% at 10 µg/mL. The most consistent and potent inhibition was observed for Dichapetalum heudelotii root fractions (DOS-19/20/21/22) and Xylopia aethiopica fruit fractions (DOS-34/45/47). DOS-20 contained stilbenoids including (E)-combretastatin A-1, combretastatin B-1, and heudelotols, and produced a strong and broad inhibition of proliferation at 10 µg/mL. DOS-34 and -47, enriched in ent-kaurane diterpenoids, exerted strong inhibition of proliferation at 10 µg/mL, with a clear loss of activity at 1 µg/mL, indicating a steep dose-response behavior. The single compound hexyl-9-oxodecanoate (DOS-8) exhibited higher activity at both 10 and 1 µg/mL in SSK41 venetoclax-resistant cells than in parental cells. Similarly, the single compound isomeranzin, derived from Clausena anisata , and the Xylopia + Bambusa precipitate showed higher activity in SSK41 venetoclax-resistant cells. Subfractions from column chromatography of a mixture of Aloe vera and T. officinale showed preferential activity in SSK41 cells and Karpas1718, with higher activity in Karpas1718 idelalisib-resistant cells than in parental cells. Discussion. We observed a strong chemotype-activity pattern: stilbenoids and ent-kaurane diterpenoids were the most potent profiles, while alkaloids exhibited narrower, context-specific effects; fatty ester-rich samples were mostly inactive. The sharp dose dependence of Dichapetalum and Xylopia fractions with activity in resistant and TP53-defective models suggests that they are priority leads for mechanism-of-action studies and optimization against drug-resistant B-cell lymphomas.
利益披露 Disclosure
F. Spriano, None.. A. J. Arribas, None.. A. Furlan, None.. J. Nketiah, None.. B. Z. Anibea, None.. A. Cavalli, None.. A. A. Mensah, None.. D. Osei-Safo, None.. F. Bertoni, None.

← 返回 AACR 2026 检索